This educational activity is provided by Haymarket Medical Education.
Supported by an educational grant from AstraZeneca
An unmet need in type 2 diabetes mellitus (T2DM) management is that few patients achieve established, evidence-based diabetes control targets and treatment goals. Complications from T2DM place a high burden on healthcare resource utilization and costs, rising incrementally with increasing severity of complications. This case study presentation is of a 42-year-old woman with T2DM with multiple comorbidities and increasing beta-cell destruction. It highlights the importance of utilizing a shared decision-making model when adding/removing an agent.
General internal medicine, internal medicine subspecialties, and other healthcare professionals with an interest in diabetes management
At the conclusion of this activity, participants should be better able to:
Describe the complex pathophysiology of T2DM, including the defects that contribute to disease progression
Review the potential glycemic and extraglycemic benefits of novel and emerging combination treatment strategies for appropriate patients with T2DM
Assess the need to initiate or intensify treatment, considering natural disease progression, side effects, glycemic/nonglycemic treatment goals, complications of diabetes, and individual patient needs
Implement strategies for more effective patient education/counseling about ongoing self-management, including treatment goals/expectations, adherence, and managing adverse events and comorbidities
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
John E. Anderson, MD (Chair) TriStar Centennial Medical Center The Frist Clinic Nashville, TN
Dr. Anderson is a consultant for Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi, Janssen, and Abbott Diabetes. He is also on the speakers’ bureaus for Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi, and Janssen.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AstraZeneca and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.